Keeping Track: US FDA Clears Another CAR-T And Another Novel ADHD Drug; Submissions Blossom

 
• By Bridget Silverman
  
Generate a summary of this article
Listen to this article
Beta

The latest news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Keeping Track Feature image
Abecma is only the second CBER original approval so far this year.

The US Food and Drug Administration’s most recent novel approvals sound familiar themes. Bristol Myers Squibb Company's Abecma (idecabtagene vicleucel) is the second novel chimeric antigen receptor T-cell (CAR-T) therapy to clear the Center for Biologics Evaluation and Research in 2021. Supernus Pharmaceuticals, Inc.'s Qelbree (viloxazine) is the second novel therapy for attention deficit hyperactivity disorder approved by the Center for Drug Evaluation and Research this year.

While Qelbree is the 15th novel approval from CDER in 2021, Abecma is only the second CBER original approval. BMS...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Approvals

EU Biosimilar Filings, Opinions And Approvals

 
• By Saba Afreen

<p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

New EU Approvals

<p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

EU Biosimilar Filings, Opinions And Approvals

 
• By Saba Afreen

<p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

More from Product Reviews

data

New EU Filings

 
• By Saba Afreen

<p>Executive Summary</p> <p>Zanidatamab, Jazz and BeiGene’s investigational treatment for biliary tract cancer, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.</p>

data

EU CHMP Opinions And MAA Updates

 
• By Saba Afreen

<p>Executive Summary</p> This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.

EU Biosimilar Filings, Opinions And Approvals

 
• By Saba Afreen

<p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>